circulating tumor DNA. The association of liquid biopsy and tissue biopsy is analyzed in multivariate models.
tive rate in the patients with lymph node or extrathoracic metastasis, such as brain and bone metastasis. Our study suggest that liquid biopsy may be considered first if the patient have NSCLC with lymph node, brain and bone metastasis. Background and Aims: This study aimed to examine the role of microRNAs (miRNAs) as potential biomarkers for non-small cell lung cancer (NSCLC). Our previous miRNA microarray profiling study in paired NSCLC tissues found that miR-126* and miR-145 were down-regulated in the tumor tissues. Restoration of miR-145 inhibited cancer cell growth in lung adenocarcinoma with epidermal growth factor receptor mutation. This study further investigate their diagnostic values in NSCLC patients.
Methods:
The expression levels of miR-126* and miR-145 were detected by real-time RT-PCR in the paired frozen lung cancer tissues with adjacent normal lung parenchyma and in the plasma of 20 NSCLC patients compared to normal controls using the locked nucleic acid miRNA PCR system. RNU6 and miR-16 were employed as endogenous reference genes. The diagnostic values of these miRNA markers were analyzed using receiver-operating characteristic (ROC) curve.
Results: The expressions of miR-126* and miR-145 were found to be significantly down-regulated in both tumor tissues and plasma compared to normal controls (P ≤ 0.03). For the diagnostic values of miR-126* and miR-145 in tissue samples, the area under the ROC curve (AUC) were 0.867 (95% CI: 0.75-0.984) and 0.83 (95% CI: 0.698-0.963), respectively. These results were in line with the findings in plasma samples, in which the AUC of miR-126* and miR-145 were 0.82 (95% CI: 0.637-1) and 0.95 (95% CI: 0.849-1), respectively.
Conclusion:
Our results confirmed the diagnostic values of miR-126* and miR-145 in NSCLC patients. These data suggested that plasma miR-126* and miR-145 may be useful non-invasive biomarkers for the clinical diagnosis of NSCLC. To further explore the clinical significance of these miRNAs, larger sample size is being retrieved for validation. Droplet digital PCR may be used for the sensitive absolute quantification of miRNAs. Bioinformatics and luciferase reporter assay can also be employed to identify the gene targets of these miRNAs. Methods: Between Dec 2014 to Dec 2016, 60 untreated patients with MPE in lung adenocarcinoma were randomly assigned to one of two groups: intrapleural injection of Bevacizumab ( 5 mg/kg) ( n = 30) and intrapleural injection of OK432 ( 5ke) once every 3 days( n = 30) , Recorded and assessed adverse events .ELISA was applied to detect the vascular endothelial growth factor (VEGF) level in serum .
Results: The Bevacizumab group: Fifteen (50%) and eleven (37%) patients achieved CR and PR, 1 case of stable (3%), 3 cases of progress (10%). The OK432 group: Thirteen (43%) and twelve (40%) patients achieved CR and PR, 2 cases of stable (7%),4 cases of progress (13%).
There was no statistically significant difference between the effective rate of the two groups (P > 0.05). The Bevacizumab group: only 1 case with
